TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Christoph Kroener
Head of IVAC Mutanome Lead Structure at BioNTech AG

Profile

Since April 2016, Christoph Kröner works as Head of IVAC Mutanome Lead Structure at BioNTech RNA Pharmaceuticals GmbH with strong focus on developmental work for BioNTech’s individualized cancer treatment programs. He has more than eight years of experience working with nucleic acids. His work focused on mRNA-based therapeutics when he joined BioNTech in 2014 as a scientist. Christoph Kröner holds a diploma and PhD in chemistry from the University of Stuttgart, Germany.

Christoph Kroener's Network

Agenda Sessions

  • Individualized Neoantigen-specific Therapy against Cancer Using messenger RNA

    , 09:30
  • Individualized Neoantigen-specific Therapy against Cancer Using messenger RNA

    , 09:30
  • Individualized Neoantigen-specific Therapy against Cancer Using messenger RNA

    , 09:30